FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 181 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Foodie Friday: Watermelon Fruit Pizza September 3, 2021 Cancer Moonshot℠ Workshop Highlights Recent Research Advances March 4, 2020 Screening People at High Risk for Pancreatic Cancer May Help Them... August 2, 2024 Begin Each Day… January 20, 2021 Load more HOT NEWS BooHoo Is Selling Bras With Subtle Patterns To Help You Check... A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... Cancer in My Community: Improving Access to Palliative Care in Indonesia Pastor Opens Homeless Shelter And Moves In To Raise Money For...
